
    
      A phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and
      Tolerability of Gefitinib 250 mg (IRESSAï¿½) as 3rd line treatment re-challenge in Patients,
      who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or
      Metastatic Non-Small Cell Lung Cancer (NSCLC) and who responded to gefitinib in 1st line and
      progressed after 2nd line chemotherapy
    
  